CEO Nils Brünner comments:
“We are very happy to be allowed to treat second and third patient simultaneously. This is possible because we have had no toxicity issues with Foxy-5 when administered to the cancer patients.”
For further information please contact:
Nils Brünner, CEO
E-mail:
nbr@wntresearch.com
Telephone: +45 2614 4708
About Foxy-5
Foxy-5 is an anti-metastatic drug candidate in clinical Phase 1. Foxy-5 represents a new concept (first-in-class) in the treatment of cancer. The drug candidate aims directly at the metastatic process. The spread of the tumor is the most common reason of death for cancer patients.
Foxy-5 is one of the first anti-metastatic drug candidates to be investigated in the clinical setting.
Foxy-5 offers a potential shift in the anticancer treatment paradigm in the treatment of many large cancer indications including breast-, colon, and prostate cancer.
About WntResearch
WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients with metastasis. The company’s lead product Foxy-5 is in phase 1 and Box-5 is in pre-clinical phase. The company is focusing on Foxy-5.